SEC Filing Summary for Castle Biosciences Inc. - Form 4 Filing

This filing details transactions by Derek J. Maetzold, President & Chief Executive Officer of Castle Biosciences Inc. (CSTL), on March 13 and March 16, 2026. Maetzold, through a Rule 10b5-1 plan, sold a total of 30,779 shares of Common Stock. The sales occurred at weighted-average prices of $25.447 on March 13 and $25.964 on March 16. Following these transactions, Maetzold directly holds 40,779 shares. The filing also lists Maetzold's indirect holdings through various trusts, including The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, and several DJM Grantor Retained Annuity Trusts, among others. The total number of shares held indirectly following these transactions is substantial, indicating significant trust-related ownership.